| |
property for sale in balchik varna brovets bansko bulgaria
News and Information Article
Funds Will Advance Clinical Development of Non-Invasive Test
for Prenatal Diagnosis
NEW HAVEN, Conn., March 8 // -- Ikonisys, Inc., a medical
technology company focused on the development of products for prenatal and
cancer diagnosis and screening and fertility, today announced the closing of a
$10 million Series D private equity financing. The round was led by Trevi
Health Ventures, with a strong syndicate of existing and other new investors,
including St. Simeon Lda, New Science Ventures, WHI Group and Lakeview Capital
Management. With this financing, Ikonisys expects to rapidly advance its
prenatal diagnostics program to FDA submission and further develop its
oncology program.
"We are excited to close this round of financing with the participation of
investors of such high quality who add significant value to our enterprise.
This financing will facilitate the completion of the clinical development of
the fetal cell detection test, a test that could significantly impact the
health care of its intended users and help position Ikonisys in the center of
an exciting segment of the diagnostic market," said Petros Tsipouras, Chairman
and Chief Executive Officer of Ikonisys.
"We are very impressed with the robotic microscopy platform Ikonisys has
developed and the progress that the Company has made in its prenatal and
cancer diagnostic product lines. Researchers and companies have for years
been seeking a prenatal diagnostic system that is accurate and non-invasive
and that can sustain high-volume throughput, and we are excited that Ikonisys
appears to be succeeding in accomplishing these goals where many others have
failed," commented Andrew Fink, Managing Director of Trevi Health Ventures.
Ikonisys has developed the Ikoniscope(TM)/IkoniLAN(TM), a robotic
microscopy system for fully automated and high-throughput rare cell detection
and analysis. The fetal cell test will provide non-invasive prenatal
diagnosis for chromosomal abnormalities by analyzing a small sample of
maternal blood to detect circulating fetal cells. The Company is also
developing several oncology products based on the utilization of its robotic
microscopy system.
About Ikonisys
Ikonisys is a medical technology company that is developing products for
prenatal and cancer diagnosis. Based on its proprietary technology, Ikonisys
aims to expand a novel field of medical diagnostic analysis, namely cell-based
diagnostics. Additional information about Ikonisys can be found at
http://www.ikonisys.com.
Contact:
Petros Tsipouras, MD
Chairman and CEO
Ikonisys, Inc.
Phone Number: 203-776-0791
Email: tsipouras@ikonisys.com
This release was issued through eReleases(TM). For more information,
visit http://www.ereleases.com.
| |
|
|
 |
property for sale in balchik varna brovets bansko bulgaria |
|
|
|
|
|
|
|
|
|
Locations
